The general increase in the potential risk of uterine cancer with tamoxifen use is lower (less than one%), and it goes back to standard inside of a number of years of stopping the drug.Progression happening six or more months following initiating the first endocrine therapy for metastatic ailment (both fulvestrant or aromatase inhibitor that contai